Stock Track | XUANZHUBIO-B Soars 6.13% at Market Open on Phase III Trial Approval for H. pylori Treatment

Stock Track04-15

XUANZHUBIO-B's stock soared 6.13% at the market open on Wednesday, following the announcement of a significant regulatory milestone for its key drug candidate.

The biopharmaceutical company received approval from China's Center for Drug Evaluation to initiate a Phase III clinical trial evaluating its drug, Anaprazole Sodium Enteric-Coated Tablets, for the eradication of Helicobacter pylori infection. The multicenter trial plans to enroll 556 adult subjects and will assess the efficacy and safety of a bismuth-containing quadruple therapy regimen.

This development represents a major expansion opportunity for Anaprazole Sodium, which was initially approved for duodenal ulcer treatment in June 2023. The H. pylori treatment market in China represents a substantial commercial opportunity, with infection rates around 44% of the population and market projections showing growth from RMB 5.5 billion in 2024 to RMB 12.6 billion by 2035.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180494741?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180494741","market":"nz","top_or_hot":-1,"title":"Stock Track | XUANZHUBIO-B Soars 6.13% at Market Open on Phase III Trial Approval for H. pylori Treatment","media":"Stock Track","content":"<p>XUANZHUBIO-B's stock soared 6.13% at the market open on Wednesday, following the announcement of a significant regulatory milestone for its key drug candidate.</p><p>The biopharmaceutical company received approval from China's Center for Drug Evaluation to initiate a Phase III clinical trial evaluating its drug, Anaprazole Sodium Enteric-Coated Tablets, for the eradication of Helicobacter pylori infection. The multicenter trial plans to enroll 556 adult subjects and will assess the efficacy and safety of a bismuth-containing quadruple therapy regimen.</p><p>This development represents a major expansion opportunity for Anaprazole Sodium, which was initially approved for duodenal ulcer treatment in June 2023. The H. pylori treatment market in China represents a substantial commercial opportunity, with infection rates around 44% of the population and market projections showing growth from RMB 5.5 billion in 2024 to RMB 12.6 billion by 2035.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | XUANZHUBIO-B Soars 6.13% at Market Open on Phase III Trial Approval for H. pylori Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | XUANZHUBIO-B Soars 6.13% at Market Open on Phase III Trial Approval for H. pylori Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-15 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XUANZHUBIO-B's stock soared 6.13% at the market open on Wednesday, following the announcement of a significant regulatory milestone for its key drug candidate.</p><p>The biopharmaceutical company received approval from China's Center for Drug Evaluation to initiate a Phase III clinical trial evaluating its drug, Anaprazole Sodium Enteric-Coated Tablets, for the eradication of Helicobacter pylori infection. The multicenter trial plans to enroll 556 adult subjects and will assess the efficacy and safety of a bismuth-containing quadruple therapy regimen.</p><p>This development represents a major expansion opportunity for Anaprazole Sodium, which was initially approved for duodenal ulcer treatment in June 2023. The H. pylori treatment market in China represents a substantial commercial opportunity, with infection rates around 44% of the population and market projections showing growth from RMB 5.5 billion in 2024 to RMB 12.6 billion by 2035.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"轩竹生物-B","start_time":0,"source_url":"","article_id":"1180494741","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180494741","pubTimestamp":1776217086,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"XUANZHUBIO-B's stock soared 6.13% at the market open on Wednesday, following the announcement of a significant regulatory milestone for its key drug candidate.The biopharmaceutical company received...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02575":"轩竹生物-B"},"translate_title":"个股轨迹|轩竹生物-B开盘大涨6.13%治疗幽门螺杆菌III期试验获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"XUANZHUBIO-B's stock soared 6.13% at the market open on Wednesday, following the announcement of a significant regulatory milestone for its key drug candidate.The biopharmaceutical company received approval from China's Center for Drug Evaluation to initiate a Phase III clinical trial evaluating its drug, Anaprazole Sodium Enteric-Coated Tablets, for the eradication of Helicobacter pylori infection. The multicenter trial plans to enroll 556 adult subjects and will assess the efficacy and safety of a bismuth-containing quadruple therapy regimen.This development represents a major expansion opportunity for Anaprazole Sodium, which was initially approved for duodenal ulcer treatment in June 2023. The H. pylori treatment market in China represents a substantial commercial opportunity, with infection rates around 44% of the population and market projections showing growth from RMB 5.5 billion in 2024 to RMB 12.6 billion by 2035.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180494741","isCrawlerRequest":true}